Rhythm stockholders elect two Class II directors, approve officer exculpation amendment

RHYTHM PHARMACEUTICALS, INC.

Jennifer Good (55.6M votes for) and Edward T. Mathers (35.2M for) elected as Class II directors.
Ernst & Young ratified as independent auditor for FY2025 with 60.6M votes for, 158k against.
Non-binding advisory vote on executive compensation approved (40.9M for, 18.1M against).
Amendment to certificate of incorporation to provide officer exculpation approved (55.5M for, 3.5M against).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

RHYTHM PHARMACEUTICALS, INC.: Amended certificate of incorporation to provide for officer exculpation from fiduciary duty breaches to the fullest extent permitted by Delaware law (effective 2025-06-25).

Change: charter amendment
Effective: 2025-06-25

Exact text from the filing

On June 24, 2025 Rhythm Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”), which had previously been adopted by the Company’s Board of Directors (the “Board”) subject to stockholder approval at the Annual Meeting.

View on SEC.gov

Browse all governance changes →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-25-008924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.